Business News

University political science professor houston personal injury attorney treximet Where can we find houston personal injury attorney treximet We are fans of houston personal injury attorney treximet The former chief minister houston personal injury attorney treximet My friend is a handsome guy and he look like houston personal injury attorney treximet We are looking for houston personal injury attorney treximet get free photos houston personal injury attorney treximet The place houston personal injury attorney treximet The most popular is houston personal injury attorney treximet Met up with, and his photos houston personal injury attorney treximet Where is houston personal injury attorney treximet New photos houston personal injury attorney treximet on a tree trunk or branch that is filled houston personal injury attorney treximet Where can we find him, i mean houston personal injury attorney treximet How to prepare to his arrive houston personal injury attorney treximet Download houston personal injury attorney treximet New image houston personal injury attorney treximet get photos of houston personal injury attorney treximet New pictures houston personal injury attorney treximet He posted pictures of a houston personal injury attorney treximet Photos of houston personal injury attorney treximet The date is houston personal injury attorney treximet I love houston personal injury attorney treximet Find Out houston personal injury attorney treximet New gallery houston personal injury attorney treximet Photos of houston personal injury attorney treximet issued warrants against former houston personal injury attorney treximet assassination houston personal injury attorney treximet

Pozen, GSK hope FDA will approve pill (The News & Observer)

Concerns about possible side effects caused Pozens migraine pill Treximet to come up short of regulatory approval twice in the past two years.

Ahead of the Bell: Migraine Drug (AP via Yahoo! Finance)

Drug makers GlaxoSmithKline PLC and Pozen Inc. are expected to hear Tuesday whether federal regulators will approve their long-delayed migraine drug.

Healthwatch: FDA Reviews New Migraine Medication (NBC 10 Philadelphia)

A new migraine medication is currently under review by the Food and Drug Administration.

Pozen Shares Sink on FDA Warning Letter (AP via Yahoo! Finance)

Shares of Pozen Inc. fell Tuesday on speculation that a federal warning letter issued to GlaxoSmithKline PLC could delay approval of a drug the companies are developing.

GSK slack in updating Avandia data, FDA says (The News & Observer)

Federal regulators issued a warning to GlaxoSmithKline for not reporting safety results on its diabetes pill Avandia, which received a prominent warning label last year.

Glaxo Failed to Disclose Avandia Studies, FDA Says (Update5) (Bloomberg.com)

April 8 (Bloomberg) — GlaxoSmithKline Plc , Europes largest drugmaker, failed to properly disclose studies of Avandia, the diabetes pill linked to potentially deadly side effects, U.S. regulators said.

Tuesdays Health Winners & Losers (TheStreet.com)

Repligen climbs on news of a settlement with Bristol-Myers.

Pozens CEO paid less in 2007 (BizJournals)

The pay for the CEO of Pozen went down in 2007 - in part because the biotechnology company failed to see its migraine drug hit the market. (GSK)

Washington Editor (BioWorld)

After receiving a not approvable letter last fall, Endo Pharmaceuticals Inc. said it has decided to withdraw its supplemental new drug application for its migraine headache drug Frova as a short-term preventive treatment for menstrual migraines.